Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
Crossref DOI link: https://doi.org/10.1186/s13023-022-02390-x
Published Online: 2022-06-13
Published Print: 2022-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rawson, Nigel S. B. http://orcid.org/0000-0001-6843-4890
Text and Data Mining valid from 2022-06-13
Version of Record valid from 2022-06-13
Article History
Received: 4 March 2022
Accepted: 6 June 2022
First Online: 13 June 2022
Declarations
:
: Not applicable.
: The author declares no competing interests.